Group 1: Financial Performance - In 2024, the company achieved a revenue of 641 million CNY, representing a growth of 10.23% compared to the previous year [4] - The net profit attributable to shareholders was 91.83 million CNY, an increase of 7.24% year-on-year [4] - R&D expenses for 2024 amounted to 23.98 million CNY, accounting for 3.74% of total revenue [3] Group 2: Product Development and Innovation - The company launched new products including "民生普瑞宝益生菌冻干粉" and "民生普瑞宝即食益生菌" [2] - In 2024, the company added 1 new drug approval, 3 invention patents, and 4 utility model patents [3] - The company is developing a new series of composite nutrient supplements, currently at various stages of R&D [6] Group 3: Market Strategy and Sales - The company reported a 23.69% revenue growth in the Central China region, attributed to targeted market strategies [5] - The vitamin and mineral supplement series saw a revenue increase of 10.47% in 2024 [6] - The company is expanding its e-commerce presence on platforms like Tmall, JD.com, and Douyin [7] Group 4: Strategic Partnerships and Collaborations - The strategic partnership with 中科嘉亿 aims to enhance the company's capabilities in the probiotics sector [4] - The company is leveraging its collaboration to expand its product offerings and market reach in the probiotics field [4] Group 5: Future Outlook and Plans - The company plans to cultivate multiple star products as part of its 2025 operational strategy [5] - Future initiatives include enhancing digital transformation and smart manufacturing to improve efficiency [3] - The company aims to explore international markets and introduce its products globally [6]

Core Viewpoint - The company is experiencing growth in the health supplement market, driven by increasing health awareness and consumer demand for preventive healthcare products, leading to a strategic focus on product innovation and market expansion [3][5][19]. Company Overview - The company operates in the pharmaceutical manufacturing industry, specifically in the OTC (over-the-counter) drug and health supplement sectors, with its main product being the 21 Jinweita Multivitamin [3][4]. - The health supplement market in China is expanding, with significant growth potential compared to developed countries, as consumer awareness and demand for dietary supplements increase [4][7]. Industry Trends - The non-prescription drug market is benefiting from a shift towards preventive healthcare, supported by national policies promoting health awareness and consumer education [5][6]. - The aging population in China is driving demand for health management products, with a notable increase in the elderly demographic, which is expected to further boost the health supplement market [8][9]. Business Performance - The company reported a revenue of 641 million yuan, a year-on-year increase of 10.23%, and a net profit of 91.83 million yuan, up 7.24% from the previous year [19]. - The company is focusing on expanding its product matrix in the health supplement sector, enhancing its brand presence, and optimizing its sales channels to improve market competitiveness [10][14]. Product and Brand Strategy - The company has a diverse product range, primarily focusing on vitamins and minerals, and is committed to continuous research and development to meet varying consumer needs [11][12]. - The brand "21 Jinweita" has established itself as a leading name in the vitamin and mineral sector, with recognition in various industry awards and rankings [13]. Marketing and Sales Network - The company has developed a comprehensive marketing network, utilizing both online and offline channels to reach consumers effectively, including major e-commerce platforms [14]. - The company is adapting its sales strategies to align with changing consumer behaviors and preferences, ensuring broad market coverage [14]. Management and Innovation - The company boasts a professional management team with extensive experience in the health product sector, focusing on innovation and compliance with industry standards [15]. - The company has established a robust core technology system for product formulation and quality control, continuously improving its capabilities [16].